Engineered immune cells take aim at tough liver cancers
NCT ID NCT06590246
Summary
This study is testing a new cell therapy called C-CAR031 for adults with advanced or recurrent liver cancer (hepatocellular carcinoma) that has a specific marker called GPC3. The therapy involves taking a patient's own immune cells, modifying them in a lab to better target the cancer, and then infusing them back. The main goals are to see if the treatment is safe and if it can shrink tumors in people who have already tried at least two other standard treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHanzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
ZhongShan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.